COMPANY

AceLink Therapeutics

AceLink Therapeutics is a clinical-stage drug development company that leverages deep understanding of glycolipid biology to develop groundbreaking therapies for diseases of glycolipid metabolism. From company website Source · Oct 12, 2026

Keywords: Fabry Disease Autosomal Dominant Polycystic Kidney AL01211

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Oct 25, 2023 Trial start Phase 2: Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease source ↗
Jun 8, 2021 Trial start Phase 1: To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06114329	Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease	Phase 2	Unknown status (ClinicalTrials.gov)	Oct 25, 2023	2024-12 (estimated)
NCT04908462	To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers	Phase 1	Completed	Jun 8, 2021	Jun 20, 2022 (actual)